Biogen's research chief talks China, neuropsychiatry and pipeline plan
Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to “look outside the walls of the company” to avoid being left behind. In her first interview since then, she told ...
View ArticleNoom cuts coaches, staff as fewer sign up
Noom has laid off employees in coaching and customer service after its bet on prescribing GLP-1 drugs wasn't enough to offset losses from its original program, Endpoints News has learned. The job cuts...
View ArticleUS biosimilar 'void' spells trouble as biologic patent expirations loom,...
While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for biosimilar developers may not materialize because of several challenges,...
View ArticleGene-edited pig kidneys will be tested in more humans soon
The FDA has cleared two new requests to test gene-edited pig kidney transplantation, including a first clinical trial of the technology. United Therapeutics announced Monday that it received the...
View ArticleOmega Therapeutics nears bankruptcy filing, lays off workers
Omega Therapeutics anticipates filing for bankruptcy within the next week, the epigenomic medicines company said in a filing, a sudden end for a company that just a year ago signed an obesity...
View ArticleMerck pauses Gardasil shipments to China
Merck is pausing HPV vaccine shipments to China “until at least mid-year” as it grapples with lower demand for the shot. The company also withdrew its $11 billion sales target for Gardasil by 2030 as ...
View ArticleAstellas shakes up management despite impressive nine-month earnings
Astellas is reorganizing its management team, and while it doesn't involve a change at the top as Daiichi Sankyo announced last week, it could still have major repercussions for drug development at ...
View ArticleRegeneron will start delivering quarterly dividends 37 years into its existence
Regeneron Pharmaceuticals, one of the original and longest-standing biotech companies, is entering the dividends arena for the first time. The Tarrytown, NY-based drugmaker surprised the market Tuesday...
View ArticleUpdated: Pfizer sticks to 2025 projections as Covid sales stabilize, R&D...
Pfizer’s high-profile, high-volatility Covid-19 franchise stabilized at the end of 2024, as the New York drugmaker pursues a revamp of its R&D operations and continues to cut costs. Pfizer’s Covid...
View ArticleBavarian Nordic’s stock sinks after 2024 revenues underwhelm
Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales despite a rise of demand for its mpox vaccines. Decreased orders for its public ...
View ArticleStudy using experimental Eli Lilly drug will try to stop Alzheimer’s decades...
Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her great-grandmother, has struck her relatives with the first signs of memory...
View ArticleHow opioid addiction treatment startup Bicycle Health reached a profit
Bicycle Health, a provider of telehealth treatment for opioid use disorder, has hit a major milestone that’s eluded many health tech startups: It turned a profit. The company, based in Boston and...
View ArticleFDA approves Supernus’ Parkinson’s drug-device after two rejections
At long last, the FDA approved Supernus Pharmaceuticals’ Parkinson’s disease treatment, which will be marketed as Onapgo. Onapgo is now approved to treat motor fluctuations in adults with advanced...
View ArticleUpdated: RFK Jr. advances out of Senate committee with Cassidy’s support
Sen. Bill Cassidy (R-LA) voted to advance Robert F. Kennedy Jr.’s nomination for HHS secretary to the full Senate, a key show of support from one of the nominee's most vocal critics on the Republican ...
View ArticleTurnstone stops TIL studies; GH Research’s $150M offering
Plus, news about Auron Therapeutics, Akribion Therapeutics, Enveric Biosciences and Valerio Therapeutics: Turnstone Biologics to discontinue TIL studies, “review strategic alternatives”: The company...
View ArticleIllumina added to China's blacklist following Biosecure Act, tariffs
China added DNA sequencing giant Illumina to a list of blacklisted entities after proposed US legislation targeted two Chinese rivals to Illumina and President Donald Trump imposed a 10% tax on all...
View ArticleTrump undercuts RFK Jr. assurances on vaccines, autism
Robert F. Kennedy Jr. is headed for Senate confirmation following Tuesday’s committee vote and a statement of support from the GOP’s biggest skeptic. But it’s still very, very unclear which Kennedy...
View ArticlePfizer says it has at least $10B available for deals in 2025
Pfizer's next deals are likely to be longer-term efforts to reload its R&D work rather than big-ticket, late-stage assets, the company's top executives said Tuesday. “Looking forward, we are...
View ArticleFDA approves Roche's ocular implant in diabetic macular edema
Roche subsidiary Genentech announced Tuesday that it won FDA approval for its eye implant Susvimo to treat diabetic macular edema, a diabetes complication that causes swelling and blurred vision....
View Article